Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips (NYSE:PHG) launched IntraSight Plus, an interventional cardiology platform cleared by the FDA 510(k) and CE marked for the USA and Europe. The system combines Class IA IVUS, iFR/FFR physiology, co-/tri-registration and real-time device visualization, and claims up to 47% system operation time savings. A first patient case occurred on March 19, 2026, enabling complete revascularization using integrated tri-registered imaging and physiology at the bedside. Commercial availability depends on market release and local regulatory requirements.
Royal Philips (NYSE: PHG) ranked No. 1 among medtech companies in the European Patent Office Technology Dashboard 2025 and remained the largest Dutch patent applicant with 1,289 European patent applications across domains and 676 Medtech filings in 2025. Philips invested > 9% of sales in R&D in 2025 and reported ~53,000 patent rights.
The company highlighted platform-based hardware, software, data and AI solutions and said its innovation improved the lives of 2 billion people in 2025, targeting 2.5 billion lives per year by 2030.
Royal Philips (NYSE: PHG) has convened its Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. The AGM is scheduled for Friday, May 8, 2026 at 10:00 CET at Hotel Okura Amsterdam.
Key items include the proposed appointment of John DeFord to the Supervisory Board; re-appointments of Paul Stoffels, Herna Verhagen, and Sanjay Poonen; and re-appointment of Roy Jakobs as President/CEO and Board of Management member, all effective May 8, 2026. The agenda also covers the 2025 Remuneration Report (advisory), a proposed Supervisory Board Remuneration Policy, adoption of financial statements, and dividend options.
Royal Philips (NYSE: PHG) proposed the appointment of John DeFord to its Supervisory Board and re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen.
Marc Harrison will step down after two terms. The Supervisory Board also reconfirmed the previously announced re-appointment proposal for Roy Jakobs as President/CEO. AGM set for 8 May 2026.
Philips Sonicare (NYSE: PHG) declared World Oral Health Night for March 20, 2026, showcasing what manual brushing can leave behind and promoting power brushing benefits.
Highlights: a public installation in New York City (Lavan Midtown, 2–8 p.m. ET), research cited that manual brushing can leave up to 50% plaque, and product claims that Sonicare removes up to 2000% more plaque with up to 62,000 bristle movements/min. The new Sonicare 6500 is said to remove 1000% more plaque versus a manual brush.
Philips (NYSE: PHG) expanded its digital pathology portfolio on March 11, 2026 with Philips IntelliSite Pathology Solution on HealthSuite, a fully cloud-enabled offering powered by Amazon Web Services to help labs scale digital workflows, store and review high-resolution pathology images, and enable remote collaboration and AI integration.
The solution builds on Philips’ FDA-cleared scanners, existing installed base and HealthSuite Integrated Diagnostics portfolio; availability and AI features are limited in certain jurisdictions, including the USA.
Philips (NYSE: PHG) showcased platform-based connected care intelligence at HIMSS26 on March 10, 2026, focusing on enterprise patient monitoring and Integrated Diagnostics.
Philips emphasized interoperable, AI-enabled platforms that link monitoring, imaging, EMR and third-party systems to create longitudinal patient visibility, reduce fragmentation, and accelerate diagnostic insight; the Future Health Index 2025 found 77% of clinicians lost time due to inaccessible patient data.
Philips Sonicare (NYSE: PHG) on March 5, 2026 unveiled two new electric toothbrush ranges, a Next-Generation Sonicare drivetrain across 5700–7300 Series, a refreshed "Feel the Care" brand platform, and sustainability upgrades to brush heads and packaging.
Key details: new motor delivering up to 62,000 bristle movements per minute, multiple MSRP tiers ($59.99–$199.99), staged retail rollouts (January–February 2026), 21-day battery life on select models, and brush heads now 70% bio-based with 100% recyclable packaging.
Philips (NYSE:PHG) introduced Rembra on March 4, 2026 — a CE-marked, 510(k)-pending CT system built for acute and high-demand imaging.
Key specs: up to 106 images/sec, throughput up to 270 patients/day, largest-in-class 85 cm bore, NanoPanel Precise XD detector with 23 lp/cm resolution and 0.25 mm detail, and a Tube for Life program covering tube replacement up to 10 years.
Royal Philips (NYSE: PHG) published its Annual Report 2025 on February 19, 2026. The report has been filed with the Netherlands Authority for the Financial Markets in ESEF and is expected to be filed on Form 20-F with the SEC later today.
The Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders on May 8, 2026. The report (ESEF and Form 20-F) is available at www.results.philips.com, and printed copies can be requested via annual.report@philips.com. Investor and media contacts are provided for further information.